A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2024
The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab with/without Topical Corticosteroid Treatment in Participants with Moderate-to-Severe Atopic Dermatitis. The study will last approximately 62 weeks.
Epistemonikos ID: 6f274dbd55c0187e7ada5db721ddf9063778590a
First added on: May 15, 2024